ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 992,21
-0,77%
DAX
19 984,32
0,74%
Brent Oil
73,44
0,00%
Bitcoin
94 272,94
0,12%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. C4 Therapeutics Inc (CCCC)

  7. C4 Therapeutics Inc (CCCC) Actualités

CCCC

C4 Therapeutics (CCCC)

C4 Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CCCC
DateHeureSourceTitreSymboleSociété
09/12/202415h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
08/12/202418h30GlobeNewswire Inc.C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderNASDAQ:CCCCC4 Therapeutics Inc
20/11/202413h00GlobeNewswire Inc.C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
18/11/202422h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CCCCC4 Therapeutics Inc
15/11/202422h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CCCCC4 Therapeutics Inc
15/11/202422h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CCCCC4 Therapeutics Inc
14/11/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CCCCC4 Therapeutics Inc
14/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CCCCC4 Therapeutics Inc
13/11/202422h58Edgar (US Regulatory)Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]NASDAQ:CCCCC4 Therapeutics Inc
12/11/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
06/11/202413h00GlobeNewswire Inc.C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialNASDAQ:CCCCC4 Therapeutics Inc
05/11/202415h00GlobeNewswire Inc.C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual MeetingNASDAQ:CCCCC4 Therapeutics Inc
31/10/202422h27Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CCCCC4 Therapeutics Inc
31/10/202412h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CCCCC4 Therapeutics Inc
31/10/202412h00GlobeNewswire Inc.C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
29/10/202421h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
28/10/202421h01GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
23/10/202400h06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CCCCC4 Therapeutics Inc
15/10/202422h01GlobeNewswire Inc.C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.NASDAQ:CCCCC4 Therapeutics Inc
09/10/202413h00GlobeNewswire Inc.C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity SummitNASDAQ:CCCCC4 Therapeutics Inc
13/09/202416h00GlobeNewswire Inc.C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
10/09/202413h00GlobeNewswire Inc.C4 Therapeutics Announces Delivery of Second Development Candidate to BiogenNASDAQ:CCCCC4 Therapeutics Inc
09/09/202400h05GlobeNewswire Inc.C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
03/09/202413h00GlobeNewswire Inc.C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
29/08/202413h00GlobeNewswire Inc.C4 Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:CCCCC4 Therapeutics Inc
14/08/202413h00GlobeNewswire Inc.C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper PresentationNASDAQ:CCCCC4 Therapeutics Inc
01/08/202413h00GlobeNewswire Inc.C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
16/07/202422h01GlobeNewswire Inc.C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
08/07/202413h00GlobeNewswire Inc.C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation DayNASDAQ:CCCCC4 Therapeutics Inc
10/06/202413h00GlobeNewswire Inc.C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CCCC

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
COIN
ADAUSD
Cardano
COIN
XRPUSD
Ripple
USI
USTECH100
US Tech 100
COIN
DOGEUSD
Dogecoin
NASDAQ
GOOGL
Alphabet
COIN
SOLUSD
Solana
SPI
SP500
S&P 500
COIN
BTCUSD
Bitcoin
EU
MC
Lvmh Moet Hennessy Louis...
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés